Oral propranolol in the management of periorbital proliferating phase infantile hemangioma / 中华整形外科杂志
Chinese Journal of Plastic Surgery
; (6): 174-177, 2011.
Article
en Zh
| WPRIM
| ID: wpr-246962
Biblioteca responsable:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To observe the efficacy and safety of oral propranolol in the treatment of periorbital proliferating phase infantile hemangioma.</p><p><b>METHODS</b>A retrospective review of patient medical records was performed. 12 patients (9 female, 3 male; 1.5-8.5 months, average 3.3 months) with periorbital proliferating phase infantile hemangioma underwent oral propranolol therapy. The dosage was slowly increased to 2 mg/kg daily in divided doses for a mean duration of 16 weeks (range 4 weeks-41 weeks). Therapeutic outcomes and safety were established by evaluating colour, size of lesion, duration of treatment and side-effects of treatment before and after treatment.</p><p><b>RESULTS</b>Of these, 9 had a signification reduction in colour and size of the lesions, 2 had no further growth. 1 is stopped therapy due to hypotension after drug administration. 11 other patients, although mild adverse effects were noted, no symptoms were severe enough to discontinue treatment.</p><p><b>CONCLUSIONS</b>Propranolol appears to be a safe and effective treatment in the management of periorbital proliferating phase infantile hemangioma.</p>
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Propranolol
/
Neoplasias Orbitales
/
Estudios Retrospectivos
/
Resultado del Tratamiento
/
Usos Terapéuticos
/
Quimioterapia
/
Hemangioma
Tipo de estudio:
Observational_studies
Límite:
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Idioma:
Zh
Revista:
Chinese Journal of Plastic Surgery
Año:
2011
Tipo del documento:
Article